The Veeda Newsletter

June 2017

INDIA NEWS

Granules India to raise funds worth Rs 500 crores through QIP

Granules India Limited, a leading pharmaceutical company has decided to give the approval to raise funds amounting to Rs 500 crores by an issue of equity shares through a Qualified Institutions Placements, subject to the approval of shareholders, as per BSE filing.

The company also reported a consolidated net profit of Rs 165 crores for the year ended March 2017, an increase of 34% as compared to Rs 123 crores for the same period in the previous year, as per BSE filing.

Read More:http://www.indiainfoline.com/article/news-top-story/granules-india-to-raise-funds-granules-india-to-raise-funds-worth-rs-500-crores-through-qip-117051100458_1.html

Natco launches Pomalid; first generic version of pomalidomide capsules in India.

NatcoPharma Limited on Wednesday, 10 May 2017, in its BSE filing said that it has launched a generic version of pomalidomide 1 mg, 2 mg, and 4 mg capsules in India. Pomalidomide is sold by Celgene Inc., in the USA, under the brand name POMALYST.

Read More:http://www.indiainfoline.com/article/news-top-story/natco-pharma-natco-launches-pomalid-first-generic-version-of-pomalidomide-capsules-in-india-117051000269_1.html

MarksansPharma's Goa plant approved by UK MHRA

Mumbai headquartered, MarksansPharma in its filling to the exchanges said that the compnay'sgoa plant has been approved by UK Medicines and Healthcare Products Regulatory Agency (UK MHRA) and can start supplying all drugs to the UK.

Read More:http://www.indiainfoline.com/article/news-top-story/marksans-pharma-marksans-pharmas-goa-plant-approved-by-uk-mhra-117051000381_1.html

FDA blasts Indian drugmaker that made investigators inspect filthy plant in the dark

A number of companies have tried to keep FDA inspectors from getting a thorough look through their manufacturing plants, but none have gone to the extraordinary lengths of the Vikshara Trading & Investments plant in Gujarat, India, whose products the FDA banned over the deceptions.

Not only did the company put off an FDA inspection for months by claiming that its workers were on strike—even though it continued to manufacture products—but once inspectors got into the plant, they were left in the dark, literally. No lights were turned on, requiring inspectors to look around with flashlights.

Read More:http://www.fiercepharma.com/manufacturing/fda-blasts-indian-plant-made-investigators-inspect-filthy-plant-dark